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Introduction: The role of surgery in addition to chemotherapy 
and radiation for stage IIIA non–small-cell lung cancer (NSCLC) 
remains controversial. Because there are limited data on the ben-
efit from surgery in this setting, we evaluated the use of combined 
modality therapy nationally and explored the outcomes with and 
without the addition of surgery.
Methods: Patient variables and treatment-related outcomes were 
abstracted for patients with clinical stage IIIA NSCLC from the 
National Cancer Database. Patients receiving chemotherapy and 
radiation were compared with those undergoing chemotherapy, radi-
ation, and surgery (CRS) in any sequence.
Results: Between 1998 and 2010, 61,339 patients underwent com-
bined modality treatment for clinical stage IIIA NSCLC. Of these, 
51,979 (84.7%) received chemotherapy and radiation while 9360 
(15.3%) underwent CRS. Patients in the CRS group were younger, 
more likely female patients and Caucasians, and had smaller tumors 
and lower Charlson comorbidity scores. The 30-day surgical mor-
tality was 200 of 8993 (2.2%). The median overall survival favored 
the CRS group in both unmatched (32.4 months versus 15.7 months, 
p < 0.001) and matched analysis based on patient characteristics 
(34.3 versus 18.4 months, p < 0.001).
Conclusions: There is significant heterogeneity in the treatment of 
stage IIIA NSCLC in the United States. Patients selected for surgery 
in addition to chemoradiation therapy seem to have better long-term 
survival.
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In the United States, more than 220,000 new patients are diagnosed with lung cancer each year.1 Among those with 
newly diagnosed non–small-cell lung cancer (NSCLC), it 
is estimated that 27% of patients present with stage III dis-
ease, for which the 5-year overall survival (OS) is typically 
less than 20%.2,3
The most common treatment modality for stage IIIA 
NSCLC is a combination of chemotherapy and radiation, 
with studies suggesting a median survival of 16 to 28 months 
when both are administered concurrently.4,5 Although concur-
rent chemoradiation has been associated with increased toxic-
ity relative to sequential treatment, it does provide a survival 
advantage.6,7 Surgical resection, in addition to chemotherapy 
and radiation, has been selectively offered to patients with 
stage IIIA lung cancer, and single-center studies report good 
outcomes with median survival up to 43 months and 5-year 
survival of 33%.8–11
Over the last decade, randomized trials have aimed to 
address the role of surgery in addition to chemotherapy and 
radiation in stage III NSCLC. In the INT-0139 trial, patients 
with stage IIIA NSCLC underwent concurrent induc-
tion chemoradiation therapy. Patients were then randomly 
assigned to the surgical group or the chemoradiation group 
where they continued radiotherapy. There was no difference 
in OS between the treatment arms, although there was an 
improvement in progression-free survival in favor of sur-
gery.12 In a European study, patients with stage IIIA NSCLC 
were administered induction chemotherapy and responding 
patients were subsequently randomly assigned to surgery or 
radiotherapy. Again, no difference in OS was seen between 
the treatment arms.13
Given the variable data from clinical trials, with ran-
domized trials not showing a survival advantage for patients 
having received surgery and smaller institutional studies sug-
gesting good long-term survival with the addition of surgery 
to chemoradiation therapy, the algorithms used by institutions 
vary widely. In addition, the penetrance and efficacy of surgi-
cal resection remain inadequately understood. The National 
Cancer Database (NCDB), a joint program of the Commission 
on Cancer of the American College of Surgeons and the 
American Cancer Society, is a nationwide oncology outcomes 
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database for more than 1500 commission-accredited cancer 
programs. Approximately, 70% of all newly diagnosed cases 
of cancer in the United States are captured at the institutional 
level and reported to the NCDB.14,15 We aimed to study the 
actual practice patterns of treatment for stage IIIA NSCLC 
in the United States and to understand the efficacy of surgical 
resection in conjunction with chemotherapy and radiation in 
this population using the NCDB.
MATERIALS AND METHODS
Using deidentified patient information from the NCDB 
participant user file, we abstracted patients with clinical stage 
IIIA NSCLC who received treatment between 1998 and 2010 
with either a combination of chemotherapy and radiation ther-
apy in any sequence (CR group) or a combination of chemo-
therapy, radiation, and surgery in any sequence (CRS group). 
Patients who did not receive either one of these two treatment 
plans (CR or CRS) were excluded. Patients who received only 
palliative treatment (as coded in the database) were excluded. 
The study was exempted by the institutional review board.
For each patient, information on patient-related vari-
ables, tumor-related variables, treatment, and short- and 
 long-term outcomes was obtained. Using information on 
race, income, and the population size of the area from which 
a patient presented, we formed dichotomized groups in 
which a patient was either Caucasian or not Caucasian, had 
an annual income less than or greater than $35,000, and pre-
sented from a rural location (regional population less than 
250,000) or an urban location, respectively. The Charlson/
Deyo score was used as a measure of comorbidity in the 
database. It was categorized as 0, 1, or greater than or equal 
to 2. The NCDB combined those with scores of 2 or greater 
into one group as very few patients had scores greater than 
2. Treatment facilities were classified as community cancer 
programs, comprehensive community cancer programs, and 
academic/research centers. Last known vital status and the 
time between diagnosis and the follow-up date were used to 
determine survival. We initially contrasted patients receiv-
ing chemotherapy and radiation (CR group) to those who 
received surgery in addition to chemotherapy and radia-
tion therapy in any sequence (CRS group) in an unmatched 
comparison. Patients in the CR group were then matched to 
those in the CRS group using a propensity score-based tech-
nique. The propensity score was the probability of receiving 
surgery during the study period, estimated using a logis-
tic regression model including age, gender, race, income, 
rural versus urban status, year of diagnosis, Charlson/Deyo 
score, tumor size, and type of facility where treatment was 
administered. These variables were selected from univari-
ate analyses comparing the CR and CRS groups. Patients 
for whom the propensity scores matched to the third deci-
mal place were matched in 1:1 fashion. Automated match-
ing was performed using the Fuzzy extension command in 
SPSS (SPSS 21.0 for Windows, SPSS Inc, Chicago, IL).16 
Recognizing that neoadjuvant chemotherapy and radiation 
followed by surgery, henceforth referred to as trimodality 
therapy, are the de facto standard for CRS in the United 
States, we performed a secondary analysis (unmatched 
and matched) restricting CRS patients only to those who 
received neoadjuvant treatment (Fig. 1).
All analyses were performed using SPSS 21.0. 
Descriptive statistics were expressed as mean ± standard devi-
ation unless otherwise specified. Independent samples t tests 
and one-way analysis of variance were used to compare con-
tinuous variables. χ2 tests were used to compare categorical 
data. OS was estimated by the Kaplan-Meier method. p less 
than 0.05 were considered statistically significant.
RESULTS
Between 1998 and 2010, 123,629 patients were diagnosed 
with clinical stage IIIA NSCLC at 1588 institutions. Of these, 
61,339 (49.6%) were treated using combined modality therapy, 
with 51,979 (84.7%) receiving chemotherapy and radiation (CR) 
and 9360 (15.3%) undergoing surgical resection in addition to 
chemotherapy and radiation (CRS). Of the CRS group, 3811 
of 6635 (57.4%) had pathologically confirmed N2 disease. For 
the entire cohort of patients receiving combined modality treat-
ment, the mean age was 65.5 ± 10.1 years and 35,167 of 61,339 
(57.3%) were male patients. Most patients were treated at either 
community comprehensive cancer programs (32,654 of 61,339, 
53.2%) or academic cancer centers (17,038 of 61,339, 27.8%).
Patients in the CRS group were younger and were 
more likely to be female patients and Caucasians (Table 1). 
Surgical patients also had higher incomes and traveled far-
ther for treatment than patients in the CR only group. Patients 
who underwent CRS had smaller tumors and lower Charlson 
comorbidity scores (Table 1). Between 1998 and 2004, 4078 
of 28,464 (14.3%) patients received CRS for definitive treat-
ment, whereas this proportion increased to 5282 of 32,875 
(16.1%, p < 0.001) from 2005 to 2010. In addition, the differ-
ence in mean survival of patients diagnosed between 1998 and 
2004 (30.57 ± 0.2 months) and those between 2005 and 2010 
(29.33 ± 0.2 months), while statistically significant (p < 0.001), 
was deemed clinically insignificant. In the CR arm, 9710 of 
38,166 (25.5%) patients received a cumulative radiation dose 
of less than 50 Gray (Gy) and 17,353 of 38,166 (45.4%) less 
than 60 Gy. In the surgical arm, 2692 of 3875 (69.5%) received 
preoperative chemotherapy. For patients receiving preoperative 
radiation in the surgical arm, mean radiation dose was 51.02 
Gy. Mean postoperative hospital stay was 6.8 ± 8.4 days, and 
the 30-day surgical mortality was 200 of 8993 (2.2%). Median 
survival for unmatched patients receiving CR versus CRS was 
15.7 versus 32.4 months, respectively (p < 0.001; Fig. 2A).
Propensity score matching between the CR and CRS 
groups yielded 5265 matched pairs. These groups were compa-
rable in age, gender, race, location (rural versus urban), income, 
comorbidities, treatment facility, and year of diagnosis (Table 2). 
Tumors in the CR group were slightly larger than those in the 
CRS group (43.7 versus 42.5 mm, p = 0.01), although the 1.2 mm 
difference was not considered clinically meaningful. In the CR 
arm, 1017 of 4963 (20.5%) patients received a cumulative radia-
tion dose of less than 50 Gy and 1977 of 4963 (39.8%) less than 
60 Gy. In the surgical arm, 2112 of 3619 (58.3%) received pre-
operative chemotherapy. For the CRS group, the mean postop-
erative hospital stay was 6.9 ± 8.4 days and 234 of 5265 (4.4%) 
patients experienced unplanned readmissions after surgery. The 
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30-day surgical mortality was 114 of 5265 (2.2%). Median sur-
vival for matched patients receiving CR versus CRS was 18.4 
versus 34.3 months, respectively (p < 0.001; Fig. 2B).
In the entire cohort, 2293 patients underwent trimodal-
ity therapy with neoadjuvant chemotherapy and radiation fol-
lowed by surgical resection. When compared with the 51,979 
patients who received CR only, patients in the trimodality 
group tended to be younger, were more likely to be female 
patients, and had smaller tumors and lower Charlson comor-
bidity scores (Table 3). For the trimodality group, the 30-day 
surgical mortality was 84 of 2291 (3.7%); 8.5% of patients 
died after pneumonectomy. Median survival for unmatched 
patients receiving CR versus CRS with neoadjuvant chemo-
therapy and radiation was 15.7 versus 36.0 months, respec-
tively (p < 0.001; Fig. 2C)
Propensity score matching between the CR only and 
trimodality groups yielded 1729 matched pairs. These 
groups were comparable in age, gender, race, location, 
income, comorbidities, tumor size, distance traveled for 
treatment, and type of treatment facility (Table 4). In the CR 
arm, 266 of 1625 (16.4%) patients received a cumulative 
radiation dose of less than 50 Gy and 583 of 1625 (35.9%) 
less than 60 Gy. For the trimodality group, the mean post-
operative hospital stay was 7.5 ± 9.9 days. The 30-day sur-
gical mortality was 67 of 1727 (3.9%). Median survival 
for matched patients receiving CR versus CRS with neo-
adjuvant chemotherapy and radiation was 19.7 versus 35.9 
months, respectively (p < 0.001; Fig. 2D). The 5-year sur-
vival for patients receiving trimodality treatment was 37.4% 
compared with 19.2% for CR.
FIGURE 1.  Consort Diagram showing schema of study subject selection and analysis.
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Given the large proportion of patients receiving radia-
tion therapy (RT) doses less than 60 Gy, the effect of RT 
dose on OS was explored. For CR patients in the unmatched 
cohort of 51,979 patients, OS for those with RT dose greater 
than or equal to 60 Gy was 19.2 months compared with 
15.7 months for the overall cohort. In the matched cohort 
of 5265 patients, OS in the CR group improved from 18.4 
to 20.5 months with greater than or equal to 60 Gy RT. In 
the CR cohort matched to trimodality therapy patients, OS 
improved from 19.7 to 22.3 months with greater than or 
equal to 60 Gy RT. However, in all comparisons of CRS 
versus CR, OS was significantly greater for CRS irrespec-
tive of RT dose (data not shown).
Of all clinical stage IIIA patients in this study, about 
90% had N2 disease whereas the rest included other sub-
groups of stage IIIA disease, such as T3N1. We performed a 
subgroup analysis of this subset (N2) and found no difference 
in findings from the analyses of the larger cohort of all stage 
IIIA patients (data not shown). Similarly, matched compari-
sons in the N2 subgroup analyses between the CR and CRS 
arms did not differ from findings in the larger group.
DISCUSSION
Our study demonstrates that there is significant heteroge-
neity in treatment of clinical stage IIIA NSCLC in the United 
States, and selected patients who undergo surgical resection, 
TABLE 1.   Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in All Patients with Clinical Stage 
IIIA non–small-cell lung cancer (NSCLC) Who Received Combination Therapy
 
Chemotherapy and Radiation  
(CR; n = 51,979)
Chemotherapy, Radiation, and Surgery  
(CRS; n = 9360) p Value
Age (yr) 66.3 ± 10.0 61.3 ± 9.9 <0.001
Male gender 30,133 (58.0%) 5034 (53.8%) <0.001
Caucasian 44,9`35 (87.1%) 8281 (89.2%) <0.001
Urban location 32,182 (65.2%) 6162 (70.2%) <0.001
Income greater than $35,000/yr 30,876 (62.4%) 6184 (69.9%) <0.001
Charlson/Deyo score (available  
n = 35,717, CR, n = 6713, CRS)
0 23,774 (66.6%) 0 4497 (67.0%) <0.001
1 8669 (24.3%) 1 1765 (26.3%)
2 3274 (9.2%) 2 451 (6.7%)
Distance traveled for treatment (miles) 37.5 ± 387.0 92.2 ± 775.4 <0.001
Tumor size (mm) 48.1 ± 39.5 43.0 ± 33.5 <0.001
Facility reporting case Community cancer program: 9464 (18.2%) Community cancer program: 1211 (12.9%) <0.001
Comprehensive community cancer program: 
28,183 (54.2%)
Comprehensive community cancer program:  
4471 (47.8%)
Academic/research program: 13,537 (26.0%) Academic/research program: 3501 (37.4%)
Other: 795 (1.5%) Other: 177 (1.9%)
Chemotherapy type Single agent: 4193 (9.1%) Single agent: 413 (5.0%)
Multiagent: 42,082  (90.9%) Multiagent: 7849 (95.0%)
Chemotherapy surgery sequence  
(available n = 4535)
Before surgery: 2185 (48.2%)
After surgery: 1843 (40.6%)
Before and after surgery: 507 (11.2%)
Cumulative radiation dose (cGy) 5914.1 ± 3831.8 (26.6% missing) 5295.0 ± 2901.8 (27.6% missing) < 0.001
Cumulative radiation dose (cGy;  
available n = 38,166)
≤4000: 5678 (14.9%)
4001–5000: 4032 (10.6%)
5001–6000: 7643 (20.0%)
> 6000: 20,813  (54.5%)
Cumulative radiation dose  
(cGy; n = 6774)
≤3500: 344 (5.1%)
3501–4500: 1971 (29.1%)
>4500: 4459 (65.8%)
Radiation surgery sequence  
(available n = 9044)
Before surgery: 4749 (52.5%)
After surgery: 4140 (45.8%)
Before and after surgery: 155 (1.7%)
Type of operation Lobectomy: 6284 (67.1%)
Pneumonectomy: 1517 (16.2%)
Other: 1559 (16.7%)
Median survival (months) 15.7 ± 0.1 32.4 ± 0.6 <0.001
This table shows an unmatched comparison. The CR group refers to patients who received chemotherapy and radiation in any sequence. The CRS group refers to patients who 
underwent chemotherapy, radiation therapy, and surgery in any sequence.
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in addition to chemotherapy and radiation, seem to have bet-
ter long-term OS. Within the framework of published guide-
lines by bodies such as the National Comprehensive Cancer 
Network, decision making in stage III NSCLC is often depen-
dent on institutional preferences, assessment of tumor bur-
den, and the patient’s physiologic reserve. A  population-based 
FIGURE 2.  Kaplan-Meier survival of patients undergoing combination chemotherapy and radiation (CR) versus chemotherapy, 
radiation, and surgery (CRS). A, This is an unmatched comparison; (B) propensity score matched comparison; (C) this is an 
unmatched comparison; and (D) propensity score matched comparison.
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Canadian study noted that while 12% of patients with stage 
III NSCLC underwent primary surgery, radiation therapy was 
part of the initial treatment for 78% and chemotherapy in 
31% of patients only.17 The usage of chemotherapy was espe-
cially lower than predicted. Similarly, we found that 15.3% of 
patients targeted for definitive treatment underwent a surgi-
cal resection and preoperative systemic therapy was used in 
only 69.5% of patients. Other large  population-based stud-
ies have found a similar lack of uniformity in treatment of 
stage III NSCLC, with up to 28% of patients receiving pal-
liative care and combination therapy being used in 26 to 47% 
of patients only.17–19 Poor performance status of patients has 
not been shown to solely account for these wide variations in 
treatment.17
We noted that urban dwellers, Caucasian patients, and 
those with higher income levels were more likely to receive 
combination CRS. The relationship between socioeconomic 
status, race, and treatment for lung cancer has been previously 
studied, and a meta-analysis concluded that patients living 
in more socioeconomically deprived circumstances are less 
likely to receive any type of treatment, especially surgery, and 
chemotherapy.20 Specifically, the association between likeli-
hood of surgery and socioeconomic status has been investi-
gated in patients with stage I and II NSCLC where surgical 
resection is standard of care. One such study describing a 
cohort of patients treated between 1991 and 1999 noted that 
black race and lower socioeconomic status were associated 
with a lower likelihood of surgery.21 Our findings from a more 
TABLE 2.  Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in Propensity Score Matched 
Patients with Clinical Stage IIIA Non–Small-cell lung cancer (NSCLC) Who Received Combination Therapy
Chemotherapy and Radiation  
(CR; n = 5265)
Chemotherapy, Radiation and Surgery  
(CRS; n = 5265) p Value
Age (yr) 62.5 ± 9.9 62.5 ± 9.3 0.856
Male gender 2790 (53.0%) 2773 (52.7%) 0.755
Caucasian 4653 (88.4%) 4652 (88.4%) 1.0
Urban location 3660 (69.5%) 3660 (69.5%) 1.0
Income >$35,000/yr 3634 (69.0%) 3607 (68.5%) 0.585
Charlson/Deyo score 0 3435 (65.2%) 0 3496 (65.8%) 0.371
1 1458 (27.7%) 1 1394 (26.5%)
2 372 (7.1%) 2 375 (7.1%)
Tumor size (mm) 43.7 ± 24.2 42.5 ± 26.6 0.01
Facility reporting case Community cancer program: 726 (13.8%) Community cancer program: 755 (14.3%) 0.708
Comprehensive community cancer program:  
2658 (50.5%)
Comprehensive community cancer program:  
2649 (50.3%)
Academic/research program: 1881(35.7%) Academic/research program: 1861(35.3%)
Distance traveled for treatment (miles) 49.0 ± 520.5 93.1 ± 787.5 0.001
Chemotherapy type Single agent: 354 (7.4%) Single agent: 216 (4.6%)
Multiagent: 4424 (92.6%) Multiagent: 4472 (95.4%)
Chemotherapy surgery sequence  
(available n = 3619)
Before surgery: 1724 (47.6%)
After surgery: 1507 (41.6%)
Before and after surgery: 388 (10.7%)
Cumulative radiation dose (cGy) 6005.0 ± 2893.2 (5.8% missing) 5339.5 ± 2707.4(9.5% missing) <0.001
Cumulative radiation dose  
(cGy; n = 4963)
≤4000: 561 (11.3%)
4001–5000: 456 (9.2%)
5001–6000: 960 (19.3%)
>6000: 2986 (60.2%)
Cumulative radiation dose  
(cGy; n = 4770)
≤3500: 206 (4.3%)
3501–4500: 1276 (26.8%)
>4500: 3288 (68.9%)
Radiation surgery sequence  
(n = 5265)
Before surgery: 2676 (50.8%)
After surgery: 2494 (47.4%)
Before and after surgery: 95 (1.8%)
Type of operation Lobectomy: 3708 (70.4%)
Pneumonectomy: 682 (13.0%)
Other: 875 (16.6%)
Median survival (months) 18.4 ± 0.3 34.3 ± 0.8 <0.001
The CR group refers to patients who received chemotherapy and radiation in any sequence. The CRS refers to patients who underwent chemotherapy, radiation therapy, and 
surgery in any sequence.
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contemporary period (1998–2010) are quite similar in patients 
treated for stage III NSCLC. We also noted that treatment at 
academic cancer centers was associated with trimodality ther-
apy including surgery. Other authors have described a closer 
relationship between higher volume centers and surgery for 
NSCLC.21 The NCDB does not provide details of hospital vol-
ume directly; however, it is likely that academic cancer centers 
have higher case volumes compared with other institutions.
The role of surgery in stage IIIA NSCLC is controver-
sial. Although the new American College of Chest Physicians 
guidelines suggest that surgery may play a role in specific stage 
IIIA patients, publications based on comprehensive reviews 
do not make any firm statements about the efficacy of sur-
gery.22 The American College of Chest Physician suggests that 
in patients with discrete N2 involvement by NSCLC identified 
preoperatively (IIIA), either definitive chemoradiation therapy 
or induction therapy followed by surgery be considered over 
either surgery or radiation alone. Several single-center cohort 
studies highlight good outcomes when surgery is performed 
in conjunction with chemoradiation therapy. These series 
demonstrate median OS ranging from 33 to 61 months with 
5-year survival of up to 43%.8–11,23–25 Four randomized trials 
have attempted to study the efficacy of surgery for stage IIIA 
disease.12,13,26,27 The Medical Research Council Lung Cancer 
Working Party trial attempted to enroll 350 patients with stage 
IIIA disease not amenable to primary surgery and random-
ize them to definitive radiotherapy or chemotherapy followed 
by resection. The trial closed because of poor accrual, with 
TABLE 3.  Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in Patients with Clinical Stage IIIA 
Non–Small-Cell Lung Cancer (NSCLC) Who Received Combination Therapy with Chemotherapy and Radiation Versus Those 
Who Received Trimodality Therapy
Chemotherapy and Radiation  
(CR; n = 51,979)
Preoperative Chemotherapy and Radiation  
(Trimodality; n = 2293) p Value
Age (yr) 66.3 ± 10.0 60.8 ± 9.8 <0.001
Male gender 30,133 (58.0%) 1166 (50.9%) <0.001
Caucasian 44,935 (87.1%) 2029 (89.2%) 0.003
Urban location 32,182 (65.2%) 1506 (70.9%) <0.001
Income >$35,000/yr 30,876 (62.4%) 1552 (72.2%) <0.001
Charlson/Deyo score(n = 35,717 CR, 
n = 2293 trimodality)
0 23,774 (66.6%) 0 1546 (67.4%) <0.001
1 8669 (24.3%) 1 607 (26.5%)
2 3274 (9.2%) 2 140 (6.1%)
Distance traveled for treatment (miles) 37.5 ± 387.0 111.8 ± 876.5 <0.001
Tumor size (mm) 48.1 ± 39.5 44.6 ± 30.1 <0.001
Facility reporting case Community cancer program: 9464 (18.2%) Community cancer program: 260 (11.3%) <0.001
Comprehensive community cancer program:  
28,183 (54.2%)
Comprehensive community cancer program:  
1120 (48.8%)
Academic/research program: 13,537 (26.0%) Academic/research program: 892 (38.9%)
Other: 795 (1.5%) Other: 21 (0.9%)
Chemotherapy type Single agent: 4193 (9.1%) Single agent: 83 (4.1%)
Multiagent: 42,082 (90.9%) Multiagent: 1940 (95.9%)
Chemotherapy surgery sequence  
(available n = 2293)
Before surgery: 1912 (83.4%)
Before and after: 381 (16.6%)
Cumulative radiation dose (cGy) 5914.1 ± 3831.8 (26.6% missing) 5249.1 ± 2339.9 (10.3% missing) <0.001
Cumulative radiation dose  
(cGy; n = 2059)
≤3500: 37 (1.8%)
3501–4500: 744 (36.1%)
>4500: 1278 (62.1%)
Cumulative radiation dose  
(cGy; n = 38,166)
≤4000: 5678 (14.9%)
4001–5000: 4032 (10.6%)
5001–6000: 7643 (20.0%)
>6000: 20,813 (54.5%)
Radiation surgery sequence Before surgery: 2220 (96.8%)
Before and after surgery: 73 (3.2%)
Type of operation Lobectomy: 1816 (79.2%)
Pneumonectomy: 342 (14.9%)
Other: 135 (5.9%)
Median survival (months) 15.7 ± 0.1 36.0 ± 1.5 <0.001
This table shows an unmatched comparison. The CR group refers to patients who received chemotherapy and radiation in any sequence. The trimodality group refers to patients 
who underwent preoperative chemotherapy and radiation therapy.
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only 48 patients randomized in 3 years.26 RTOG 89-01 treated 
patients with confirmed N2 disease with induction chemother-
apy and randomized them to either surgery or RT, followed by 
consolidation chemotherapy for both arms. The trial accrued 
75 patients toward a goal of 224 patients. No significant dif-
ference was noted in the median survival time between the 
surgical and radiation arms. (19.4 versus 17.4 months).27
Among the studies that met enrollment goals, the 
 INT-0139 trial treated patients with positive N2 nodes with 
concurrent induction chemotherapy plus radiotherapy.12 If no 
progression occurred, patients in the surgical group under-
went resection and those in the chemoradiation group con-
tinued radiotherapy. A total of 396 patients were examined 
with no difference noted in the OS between the two groups 
(23.6 versus 22.2 months). In an exploratory analysis, OS 
was improved for patients who underwent lobectomy (33.6 
months), but not pneumonectomy (18.9 months), versus che-
motherapy and radiotherapy. This study is criticized for an 
unusually high mortality rate of 26% after pneumonectomy 
that may have diluted any OS advantage in the surgical arm. 
The 30-day mortality rate after pneumonectomy follow-
ing induction chemoradiation in our study was 8.5%, which 
is line with the 3 to 8% operative mortality in several pre-
vious reports.28–30 Finally, in the European Organization for 
Research and Treatment of Cancer-Lung Cancer Group study, 
patients with stage IIIA-N2 NSCLC were given three cycles of 
induction chemotherapy. Responding patients were random-
ized to surgical resection or radiotherapy. Median survival for 
patients assigned to surgery versus radiotherapy was 16.4 ver-
sus 17.5 months, respectively.13 Surprisingly, nearly 55% of 
TABLE 4.   Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in Propensity Score Matched 
Patients with Clinical Stage IIIA Non–Small-Cell Lung Cancer (NSCLC) Who Received Combination Therapy with Chemotherapy 
and Radiation Versus Those Who Received Trimodality Therapy
Chemotherapy and Radiation  
(CR; n = 1729)
Preoperative Chemotherapy and Radiation  
(Trimodality; n = 1729) p Value
Age (yr) 61.9 ± 9.9 61.7 ± 9.4 0.686
Male gender 921 (53.3%) 886 (51.2%) 0.247
Caucasian 1527 (88.3%) 1534 (88.7%) 0.749
Urban location 1232 (71.3%) 1212 (70.1%) 0.478
Income >$35,000/yr 1241 (71.8%) 1232 (71.3%) 0.763
Charlson/Deyo score 0 1170 (67.7%) 0 1164 (67.3%) 0.775
1 459 (26.5%) 1 455 (26.3%)
2 100 (5.8%) 2 110 (6.4%)
Distance traveled for treatment (miles) 78.0 ± 716.0 115.3 ± 902.0 0.178
Tumor size (mm) 44.9 ± 24.7 44.9 ± 31.6 0.996
Facility reporting case Community cancer program: 189 (10.9%) Community cancer program: 213 (12.3%) 0.433
Comprehensive community cancer program:  
904 (52.3%)
Comprehensive community cancer program:  
896 (51.8%)
Academic/research program: 636 (36.8%) Academic/research program: 620 (35.9%)
Chemotherapy type Single agent: 98 (6.2%) Single agent: 61 (4.0%)
Multiagent: 1487 (93.8%) Multiagent: 1477 (96.0%)
Chemotherapy surgery sequence  
(available n = 1729)
Before surgery: 1448 (83.7%)
Before and after surgery: 281 (16.3%)
Cumulative radiation dose (cGy) 6263.4 ± 3798.9 (6.1% missing) 5279.0 ± 2606.8 (9.8% missing) <0.001
Cumulative radiation dose  
(cGy; n = 1560)
≤3500: 25 (1.6%)
3501–4500: 561 (36.0%)
>4500: 974 (62.4%)
Cumulative radiation dose  
(cGy; n = 1625)
≤4000: 156 (9.6%)
4001–5000: 110 (6.8%)
5001–6000: 317 (19.5%)
>6000: 1042 (64.1%)
Radiation surgery sequence Radiation before surgery: 1674 (96.8%)
Radiation before and after surgery: 55 (3.2%)
Type of operation Lobectomy: 1372 (79.4%)
Pneumonectomy: 257 (14.9%) 
Other: 100 (5.8%)
Median survival (months) 19.7 ± 0.6 35.9 ± 1.6 <0.001
The CR group refers to patients who received chemotherapy and radiation in any sequence. The trimodality group refers to patients who underwent preoperative chemotherapy 
and radiation therapy.
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surgical patients in this trial underwent a pneumonectomy and 
the median survival after pneumonectomy was 13.4 months 
compared with 25.4 months after a lobectomy. Less than 15% 
of patients in the trimodality group in our study underwent a 
pneumonectomy.
An important finding in our study is the wide variabil-
ity in the application of individual treatment modalities. For 
definitive therapy with CR, doses of 60 Gy or higher are rec-
ommended based on prospective data demonstrating inferior 
survival at lower doses.31 The recommended dose for preop-
erative radiotherapy is 45 Gy or higher, although no such dose 
response has been suggested in this setting.22 In the overall 
unmatched cohort, the mean radiation dose for CR was 59.14 
Gy with 25% of patients receiving a cumulative dose of less 
than 50 Gy and 45% of patients receiving less than 60 Gy. The 
implication for such a large proportion of patients with poten-
tially curable stage IIIA NSCLC being treated with suboptimal 
doses is significant and will be explored further in a separate 
analysis. In the CRS cohort, the mean radiation dose was 52.95 
Gy, and 35% of patients received a cumulative dose of less than 
45 Gy. Similarly, nearly 10% of patients in the CR cohort and 
5% in the CRS cohort were treated with single agent chemo-
therapy although dual agent chemotherapy is the standard of 
care. More than 15% of surgical patients underwent sublobar 
lung resection, despite lobectomy (or pneumonectomy) being 
widely considered to be the appropriate operation for stage 
IIIA disease. Even rigorously conducted clinical trials demon-
strate a degree of nonadherence to protocol. Investigators in the 
INT-0139 trial administered radiotherapy per protocol or with 
acceptable variation to 96% patients in the trimodality group 
and 79% in the chemoradiation only group.12 In the same study, 
95% of patients in the trimodality arm and 92% in the chemo-
radiation arm received appropriate chemotherapy per protocol, 
and only 2% of patients underwent a sublobar resection. The 
higher levels of deviation from recommended guidelines in 
this cohort are likely because of a variety of reasons, not all 
of which imply a lack of adherence. For an individual patient, 
issues of comorbidity and patient preferences may preclude 
optimal treatment. However, it seems equally likely given the 
large numbers of patients for which less than optimal treatment 
was delivered that lack of a multidisciplinary team approach, 
low patient volume, and lack of awareness of recommended 
treatment options may contribute as well.
Our study has some strengths and limitations when 
compared with previous publications. It includes information 
from a national database that reflects actual practice patterns 
for all environments where patients with lung cancer receive 
care. Thus, the findings are more likely to be generalizable 
to the population when compared with trials conducted with 
strict entry criteria at major cancer centers. The relatively 
large sample size available for primary and secondary analy-
ses is another advantage compared with prospective studies 
where subset analysis may be underpowered. However, our 
retrospective analysis may miss significant selection bias in 
treatment allocation, such that early disease may have been 
preferentially allocated to the CRS treatment group. We 
attempted to overcome this by propensity score matching 
patients based on available variables associated with treatment 
allocation to surgery but the process potentially misses impor-
tant variables not recorded in the database. We attempted to 
control for tumor burden by matching on size of the lung mass, 
but detailed information about the size and number of lymph 
nodes involved is unavailable. The accuracy of individual 
observations in large databases is arguably lower than that in 
closely monitored clinical trials; however, the general trends 
of perioperative outcomes and long-term survival we observed 
is similar to prior cohort studies. In addition, although all the 
included patients were clinical stage IIIA, most of the patho-
logic staging information was missing. Pathologic stage data 
were only available for 7% of the patients in the CR arm and 
approximately 36% of patients in the CRS arm had miss-
ing pathologic staging data. This missing pathologic staging 
information adds potential bias as this may have led to under-
staged patients in the CR group. The magnitude of mediastinal 
disease is important in consideration of surgery; however, a 
comparison of the degree of nodal involvement was not pos-
sible because nodal information was available for less than 
17% of patients in the CR group and missing for a significant 
proportion of the surgical group.
We conclude that there is significant variability in treat-
ment of patients with clinical stage IIIA NSCLC in the United 
States and patients selected for surgery in addition to chemo-
therapy and radiation seem to show better long-term survival 
relative to chemotherapy and radiation alone. We recommend 
that patients with stage IIIA NSCLC should be discussed at a 
multidisciplinary meeting that includes a medical oncologist, 
radiation oncologist, and thoracic surgeon.
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